

Simon J Davies

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/60948/publications.pdf>

Version: 2024-02-01

165
papers

7,585
citations

71102

41
h-index

58581

82
g-index

169
all docs

169
docs citations

169
times ranked

5202
citing authors

#	ARTICLE	IF	CITATIONS
1	The Current State of Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2016, 27, 3238-3252.	6.1	366
2	Survival of Functionally Anuric Patients on Automated Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2003, 14, 2948-2957.	6.1	353
3	Peritoneal Glucose Exposure and Changes in Membrane Solute Transport with Time on Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2001, 12, 1046-1051.	6.1	341
4	Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrology Dialysis Transplantation, 2002, 17, 1085-1092.	0.7	328
5	Icodextrin Improves the Fluid Status of Peritoneal Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2003, 14, 2338-2344.	6.1	328
6	What really happens to people on long-term peritoneal dialysis?. Kidney International, 1998, 54, 2207-2217.	5.2	315
7	Interleukin-6 Signaling Drives Fibrosis in Unresolved Inflammation. Immunity, 2014, 40, 40-50.	14.3	297
8	Comorbidity, urea kinetics, and appetite in continuous ambulatory peritoneal dialysis patients: Their interrelationship and prediction of survival. American Journal of Kidney Diseases, 1995, 26, 353-361.	1.9	264
9	The role of bioimpedance and biomarkers in helping to aid clinical decision-making of volume assessments in dialysis patients. Kidney International, 2014, 86, 489-496.	5.2	235
10	Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 96, 37-47.	5.2	235
11	Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney International, 2004, 66, 2437-2445.	5.2	199
12	Independent Effects of Systemic and Peritoneal Inflammation on Peritoneal Dialysis Survival. Journal of the American Society of Nephrology: JASN, 2013, 24, 2071-2080.	6.1	161
13	Trace gases in breath of healthy volunteers when fasting and after a protein-calorie meal: a preliminary study. Journal of Applied Physiology, 1999, 87, 1584-1588.	2.5	160
14	International Society for Peritoneal Dialysis practice recommendations: Prescribing high-quality goal-directed peritoneal dialysis. Peritoneal Dialysis International, 2020, 40, 244-253.	2.3	159
15	Longitudinal membrane function in functionally anuric patients treated with APD: Data from EAPOS on the effects of glucose and icodextrin prescription. Kidney International, 2005, 67, 1609-1615.	5.2	158
16	Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2020, 97, 861-876.	5.2	126
17	The Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS): Unifying Efforts to Inform Practice and Improve Global Outcomes in Peritoneal Dialysis. Peritoneal Dialysis International, 2016, 36, 297-307.	2.3	107
18	Plasma Volume, Albumin, and Fluid Status in Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1463-1470.	4.5	106

#	ARTICLE	IF	CITATIONS
19	Human Neutrophil Clearance of Bacterial Pathogens Triggers Anti-Microbial $\hat{\imath}$ T Cell Responses in Early Infection. PLoS Pathogens, 2011, 7, e1002040.	4.7	106
20	Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Family Practice, 2013, 30, 247-255.	1.9	99
21	Establishing a Core Outcome Set for Peritoneal Dialysis: Report of the SONG-PD (Standardized) Tj ETQq1 1 0.784314 rgBT /Overlock Diseases, 2020, 75, 404-412.	1.9	92
22	The peritoneal osmotic conductance is low well before the diagnosis of encapsulating peritoneal sclerosis is made. Kidney International, 2010, 78, 611-618.	5.2	91
23	Isoprene levels in the exhaled breath of 200 healthy pupils within the age range 7â€“18 years studied using SIFT-MS. Journal of Breath Research, 2010, 4, 017101.	3.0	90
24	Peritoneal Protein Clearance and not Peritoneal Membrane Transport Status Predicts Survival in a Contemporary Cohort of Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1201-1206.	4.5	85
25	An update on peritoneal dialysis solutions. Nature Reviews Nephrology, 2012, 8, 224-233.	9.6	82
26	Quantification of breath isoprene using the selected ion flow tube mass spectrometric analytical method. , 1999, 13, 1733-1738.		81
27	Bioimpedance-defined overhydration predicts survival in end stage kidney failure (ESKF): systematic review and subgroup meta-analysis. Scientific Reports, 2018, 8, 4441.	3.3	80
28	Quantification of ammonia in human breath by the selected ion flow tube analytical method using H3O+ and O2+ precursor ions. , 1998, 12, 763-766.		74
29	The effects of low-sodium peritoneal dialysis fluids on blood pressure, thirst and volume status. Nephrology Dialysis Transplantation, 2009, 24, 1609-1617.	0.7	74
30	Peritoneal dialysisâ€™ current status and future challenges. Nature Reviews Nephrology, 2013, 9, 399-408.	9.6	74
31	Patient Acceptability of the Yorkshire Dialysis Decision AID (YODDA) Booklet: A Prospective Non-Randomized Comparison Study across 6 Predialysis Services. Peritoneal Dialysis International, 2016, 36, 374-381.	2.3	73
32	Determinants of Peritoneal Membrane Function Over Time. Seminars in Nephrology, 2011, 31, 172-182.	1.6	65
33	Breath analysis of ammonia, volatile organic compounds and deuterated water vapor in chronic kidney disease and during dialysis. Bioanalysis, 2014, 6, 843-857.	1.5	65
34	Patientsâ€™ Perceptions of Information and Education for Renal Replacement Therapy: An Independent Survey by the European Kidney Patients' Federation on Information and Support on Renal Replacement Therapy. PLoS ONE, 2014, 9, e103914.	2.5	59
35	Integrated Care. Peritoneal Dialysis International, 2001, 21, 269-274.	2.3	51
36	Longitudinal relationships between fluid status, inflammation, urine volume and plasma metabolites of icodextrin in patients randomized to glucose or icodextrin for the long exchange. Nephrology Dialysis Transplantation, 2008, 23, 2982-2988.	0.7	50

#	ARTICLE	IF	CITATIONS
37	Incremental peritoneal dialysis. <i>Peritoneal Dialysis International</i> , 2020, 40, 320-326.	2.3	50
38	International Variations in Peritoneal Dialysis Utilization and Implications for Practice. <i>American Journal of Kidney Diseases</i> , 2019, 74, 101-110.	1.9	49
39	Peritoneal inflammation precedes encapsulating peritoneal sclerosis: results from the GLOBAL Fluid Study. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 480-486.	0.7	47
40	Longitudinal bioimpedance vector plots add little value to fluid management of peritoneal dialysis patients. <i>Kidney International</i> , 2016, 89, 487-497.	5.2	45
41	Combining Near-Subject Absolute and Relative Measures of Longitudinal Hydration in Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1791-1798.	4.5	43
42	Preserving residual renal function in peritoneal dialysis: volume or biocompatibility?. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2620-2622.	0.7	43
43	Ethical issues in dialysis therapy. <i>Lancet, The</i> , 2017, 389, 1851-1856.	13.7	42
44	ISPD recommendations for the evaluation of peritoneal membrane dysfunction in adults: Classification, measurement, interpretation and rationale for intervention. <i>Peritoneal Dialysis International</i> , 2021, 41, 352-372.	2.3	42
45	What is the Link between Poor Ultrafiltration and Increased Mortality in Anuric Patients on Automated Peritoneal Dialysis? Analysis of Data from Eapos. <i>Peritoneal Dialysis International</i> , 2006, 26, 458-465.	2.3	39
46	Hypoalbuminaemia, systemic albumin leak and endothelial dysfunction in peritoneal dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 4437-4445.	0.7	38
47	Supportive care for end-stage kidney disease: an integral part of kidney services across a range of income settings around the world. <i>Kidney International Supplements</i> , 2020, 10, e86-e94.	14.2	36
48	Permeability of Peritoneal and Glomerular Capillaries: What are the Differences According to Pore Theory?. <i>Peritoneal Dialysis International</i> , 2011, 31, 249-258.	2.3	35
49	Biocompatible Solutions and Long-Term Changes in Peritoneal Solute Transport. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1526-1533.	4.5	34
50	UK National Survey of Practice Patterns of Fluid Volume Management in Haemodialysis Patients: A Need for Evidence. <i>Blood Purification</i> , 2016, 41, 324-331.	1.8	33
51	Dopexamine Has No Additional Benefit in High-Risk Patients Receiving Goal-Directed Fluid Therapy Undergoing Major Abdominal Surgery. <i>Anesthesia and Analgesia</i> , 2011, 112, 130-138.	2.2	32
52	Peritoneal Solute Transport and Inflammation. <i>American Journal of Kidney Diseases</i> , 2014, 64, 978-986.	1.9	32
53	miR-21 Promotes Fibrogenesis in Peritoneal Dialysis. <i>American Journal of Pathology</i> , 2017, 187, 1537-1550.	3.8	30
54	Exploring new evidence of the clinical benefits of icodextrin solutions. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, ii47-ii50.	0.7	29

#	ARTICLE	IF	CITATIONS
55	Low Serum Potassium Levels and Clinical Outcomes in Peritoneal Dialysis—International Results from PDOPPS. <i>Kidney International Reports</i> , 2021, 6, 313-324.	0.8	29
56	Relationship of Demographic, Dietary, and Clinical Factors to the Hydration Status of Patients on Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2004, 24, 231-239.	2.3	28
57	Challenges of access to kidney care for children in low-resource settings. <i>Nature Reviews Nephrology</i> , 2021, 17, 33-45.	9.6	28
58	Overfill or Ultrafiltration? We Need to be Clear. <i>Peritoneal Dialysis International</i> , 2006, 26, 449-451.	2.3	27
59	Heart failure and chronic obstructive pulmonary disease multimorbidity at hospital discharge transition: a study of patient and carer experience. <i>Health Expectations</i> , 2015, 18, 2401-2412.	2.6	27
60	International comparison of peritoneal dialysis prescriptions from the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). <i>Peritoneal Dialysis International</i> , 2020, 40, 310-319.	2.3	27
61	Insulin resistance in cardiovascular disease, uremia, and peritoneal dialysis. <i>Trends in Endocrinology and Metabolism</i> , 2021, 32, 721-730.	7.1	27
62	Clinical Outcomes after Failed Renal Transplantation—Does Dialysis Modality Matter?. <i>Seminars in Dialysis</i> , 2008, 21, 239-244.	1.3	26
63	Longitudinal Study of Small Solute Transport and Peritoneal Protein Clearance in Peritoneal Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 326-334.	4.5	26
64	Reflections on the Academic Policy Analysis Process and the UK Identity Cards Scheme. <i>Information Society</i> , 2007, 23, 51-58.	2.9	25
65	A non-invasive, on-line deuterium dilution technique for the measurement of total body water in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2064-2070.	0.7	25
66	A Collaborative Approach to Understanding EPS: The European Perspective. <i>Peritoneal Dialysis International</i> , 2011, 31, 245-248.	2.3	24
67	A prospective, proteomics study identified potential biomarkers of encapsulating peritoneal sclerosis in peritoneal effluent. <i>Kidney International</i> , 2017, 92, 988-1002.	5.2	24
68	The use of bioimpedance spectroscopy to guide fluid management in patients receiving dialysis. <i>Current Opinion in Nephrology and Hypertension</i> , 2018, 27, 406-412.	2.0	24
69	International Anemia Prevalence and Management in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2019, 39, 539-546.	2.3	24
70	Transition between Different Renal Replacement Modalities: Gaps in Knowledge and Care—the Integrated Research Initiative. <i>Peritoneal Dialysis International</i> , 2019, 39, 4-12.	2.3	24
71	A detailed analysis of sodium removal by peritoneal dialysis: comparison with predictions from the three-pore model of membrane function. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 1192-1200.	0.7	23
72	Summary of the 5th Edition of the Renal Association Clinical Practice Guidelines (2009—2012). <i>Nephron Clinical Practice</i> , 2011, 118, c27-c70.	2.3	23

#	ARTICLE	IF	CITATIONS
73	Proof-of-principle study to detect metabolic changes in peritoneal dialysis effluent in patients who develop encapsulating peritoneal sclerosis. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2502-2510.	0.7	23
74	Volume management as a key dimension of a high-quality PD prescription. <i>Peritoneal Dialysis International</i> , 2020, 40, 282-292.	2.3	23
75	Peritoneal Protein Clearance Is a Function of Local Inflammation and Membrane Area Whereas Systemic Inflammation and Comorbidity Predict Survival of Incident Peritoneal Dialysis Patients. <i>Frontiers in Physiology</i> , 2019, 10, 105.	2.8	22
76	Expanding Utilization of Home Dialysis: An Action Agenda From the First International Home Dialysis Roundtable. <i>Kidney Medicine</i> , 2021, 3, 635-643.	2.0	22
77	Impact of the implementation of an assisted peritoneal dialysis service on peritoneal dialysis initiation. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1595-1601.	0.7	20
78	What is the link between poor ultrafiltration and increased mortality in anuric patients on automated peritoneal dialysis? Analysis of data from EAPOS. <i>Peritoneal Dialysis International</i> , 2006, 26, 458-65.	2.3	20
79	Influence of Convection on the Diffusive Transport and Sieving of Water and Small Solutes across the Peritoneal Membrane. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 437-443.	6.1	19
80	Histological and Clinical Findings in Patients with Post-Transplantation and Classical Encapsulating Peritoneal Sclerosis: A European Multicenter Study. <i>PLoS ONE</i> , 2014, 9, e106511.	2.5	18
81	Rationale and design of BISTRO: a randomized controlled trial to determine whether bioimpedance spectroscopy-guided fluid management maintains residual kidney function in incident haemodialysis patients. <i>BMC Nephrology</i> , 2017, 18, 138.	1.8	17
82	Ultrafiltration for acute decompensated cardiac failure: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2017, 228, 122-128.	1.7	17
83	Strategic plan for integrated care of patients with kidney failure. <i>Kidney International</i> , 2020, 98, S117-S134.	5.2	17
84	The osmo-metabolic approach: a novel and tantalizing glucose-sparing strategy in peritoneal dialysis. <i>Journal of Nephrology</i> , 2021, 34, 503-519.	2.0	17
85	Achieving Euvolemia in Peritoneal Dialysis Patients: A Surprisingly Difficult Proposition. <i>Seminars in Dialysis</i> , 2010, 23, 456-461.	1.3	16
86	Assisted peritoneal dialysis across Europe: Practice variation and factors associated with availability. <i>Peritoneal Dialysis International</i> , 2021, 41, 533-541.	2.3	16
87	Spinal meningioma: relationship between degree of cord compression and outcome. <i>British Journal of Neurosurgery</i> , 2017, 31, 209-211.	0.8	15
88	Overfill or ultrafiltration? We need to be clear. <i>Peritoneal Dialysis International</i> , 2006, 26, 449-51.	2.3	15
89	UK Renal Registry 19th Annual Report: Chapter 13 Home Therapies in 2015: National and Centre-specific Analyses. <i>Nephron</i> , 2017, 137, 297-326.	1.8	14
90	The Elusive Promise of Bioimpedance in Fluid Management of Patients Undergoing Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 597-599.	4.5	14

#	ARTICLE	IF	CITATIONS
91	Variation in Peritoneal Dialysis Time on Therapy by Country. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 861-871.	4.5	14
92	Estimating risk of encapsulating peritoneal sclerosis accounting for the competing risk of death. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1585-1591.	0.7	13
93	The role of kidney transplantation as a component of integrated care for chronic kidney disease. <i>Kidney International Supplements</i> , 2020, 10, e78-e85.	14.2	13
94	A genome-wide association study suggests correlations of common genetic variants with peritoneal solute transfer rates in patients with kidney failure receiving peritoneal dialysis. <i>Kidney International</i> , 2021, 100, 1101-1111.	5.2	13
95	Unraveling the mechanisms of progressive peritoneal membrane fibrosis. <i>Kidney International</i> , 2016, 89, 1185-1187.	5.2	12
96	Peritoneal Ultrafiltration for Heart Failure: Lessons from a Randomized Controlled Trial. <i>Peritoneal Dialysis International</i> , 2019, 39, 486-489.	2.3	12
97	Mortality Trends After Transfer From Peritoneal Dialysis to Hemodialysis. <i>Kidney International Reports</i> , 2022, 7, 1062-1073.	0.8	12
98	Achieving Euvolemia in Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2007, 27, 514-517.	2.3	10
99	Timing of dialysis initiation and choice of dialysis modality. <i>Nature Reviews Nephrology</i> , 2011, 7, 66-68.	9.6	10
100	Extending the role of peritoneal dialysis: can we win hearts and minds?. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1648-1654.	0.7	10
101	Insights on Peritoneal Dialysis in China. <i>Peritoneal Dialysis International</i> , 2018, 38, 16-18.	2.3	10
102	Implementation of PDOPPS in a middle-income country: Early lessons from Thailand. <i>Peritoneal Dialysis International</i> , 2021, , 089686082199395.	2.3	10
103	Renal Association Clinical Practice Guideline on Peritoneal Dialysis. <i>Nephron Clinical Practice</i> , 2011, 118, c287-c310.	2.3	9
104	Accuracy of the estimation of K_t/V and the implications this has when applying K_t/V urea for measuring dialysis dose in peritoneal dialysis. <i>Peritoneal Dialysis International</i> , 2020, 40, 261-269.	2.3	9
105	Patients' experiences of transitioning between different renal replacement therapy modalities: A qualitative study. <i>Peritoneal Dialysis International</i> , 2020, 40, 548-555.	2.3	9
106	Outcome measures for technique survival reported in peritoneal dialysis: A systematic review. <i>Peritoneal Dialysis International</i> , 2022, 42, 279-287.	2.3	9
107	What have we Learned about PD from Recent Major Clinical Trials?. <i>Peritoneal Dialysis International</i> , 2007, 27, 131-135.	2.3	8
108	PD in the UK: The Past, Present, and Future. <i>Peritoneal Dialysis International</i> , 2011, 31, 34-35.	2.3	8

#	ARTICLE	IF	CITATIONS
109	Update on the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). <i>Peritoneal Dialysis International</i> , 2014, 34, 332-332.	2.3	8
110	The second Global Kidney Health Summit outputs: developing a strategic plan to increase access to integrated end-stage kidney disease care worldwide. <i>Kidney International Supplements</i> , 2020, 10, e1-e2.	14.2	8
111	Effect of change in renal replacement therapy modality on laboratory variables: a cohort study from the UK Renal Registry. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2877-2882.	0.7	7
112	Dispersal kinetics of deuterated water in the lungs and airways following mouth inhalation: real-time breath analysis by flowing afterglow mass spectrometry (FA-MS). <i>Journal of Breath Research</i> , 2010, 4, 017109.	3.0	7
113	Assisted peritoneal dialysis performed by caregivers and its association with patient outcomes. <i>Peritoneal Dialysis International</i> , 2022, 42, 602-614.	2.3	7
114	Article Commentary: Do We Really Know the Meaning of Sodium Removal?. <i>Peritoneal Dialysis International</i> , 2011, 31, 383-386.	2.3	6
115	Towards Standardized Reporting in Studies of Encapsulating Peritoneal Sclerosis. <i>Peritoneal Dialysis International</i> , 2013, 33, 482-486.	2.3	6
116	What are the Consequences of Volume Expansion in Chronic Dialysis Patients?. <i>Seminars in Dialysis</i> , 2015, 28, 239-242.	1.3	6
117	Glomerular Injury Induced by Hydrogen Peroxide: Modifying Influence of Ace Inhibitors. <i>Free Radical Research Communications</i> , 1992, 17, 271-278.	1.8	5
118	Are PD patients with or without residual renal function qualitatively different—or are they simply at different stages of the continuum of progressive uraemia?. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 270-272.	0.7	5
119	Understanding the variability in Ultrafiltration Obtained with Icodextrin. <i>Peritoneal Dialysis International</i> , 2009, 29, 407-411.	2.3	5
120	Long-Term Changes in Solute and Water Transport. <i>Contributions To Nephrology</i> , 2009, 163, 15-21.	1.1	5
121	Prospective Safety Study of Bardoxolone Methyl in Patients with Type 2 Diabetes Mellitus, End-Stage Renal Disease and Peritoneal Dialysis. <i>Contributions To Nephrology</i> , 2012, 178, 157-163.	1.1	5
122	What has balANZ taught us about balancing ultrafiltration with * membrane preservation?. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1971-1974.	0.7	5
123	Are Peritoneal Dialysis Center Characteristics a Modifiable Risk Factor to Improve Peritoneal Dialysis Outcomes?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1032-1034.	4.5	5
124	United Kingdom Catheter Study “ Protocol Synopsis. <i>Peritoneal Dialysis International</i> , 2018, 38, 113-118.	2.3	5
125	Longitudinal measurements of total body water and body composition in healthy volunteers by online breath deuterium measurement and other near-subject methods. <i>International Journal of Body Composition Research</i> , 2004, 2, 99-106.	0.5	5
126	A new comorbidity index for estimating mortality risk in ESRD. <i>Nature Reviews Nephrology</i> , 2010, 6, 391-393.	9.6	4

#	ARTICLE	IF	CITATIONS
127	Injection of deuterated water into the pulmonary/alveolar circulation; measurement of HDO in exhaled breath and implications to breath analysis. <i>Journal of Breath Research</i> , 2012, 6, 036005.	3.0	4
128	Transition between home dialysis modalities: another piece in the jigsaw of the integrated care pathway. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1781-1783.	0.7	4
129	Getting to grips with individual variation in membrane function. <i>Peritoneal Dialysis International</i> , 2005, 25, 35-7.	2.3	4
130	International Icodextrin Use and association with peritoneal membrane function, fluid removal, patient and technique survival. <i>Kidney360</i> , 0, , 10.34067/KID.0006922021.	2.1	4
131	Spiritual well-being and its relationship with patient characteristics and other patient-reported outcomes in peritoneal dialysis patients: Findings from the PDOPPS. <i>Nephrology</i> , 2022, 27, 621-631.	1.6	4
132	Analgesia dose prescribing and estimated glomerular filtration rate decline: a general practice database linkage cohort study. <i>BMJ Open</i> , 2014, 4, e005581-e005581.	1.9	3
133	United Kingdom Catheter Study – Protocol Synopsis. <i>Peritoneal Dialysis International</i> , 2018, 38, 113-118.	2.3	3
134	Barriers and opportunities to increase PD incidence and prevalence: Lessons from a European Survey. <i>Peritoneal Dialysis International</i> , 2021, 41, 089686082110349.	2.3	3
135	How do patients and their family members experience the transition from peritoneal dialysis to in-centre haemodialysis? A multisite qualitative study in England and Australia. <i>Peritoneal Dialysis International</i> , 2022, 42, 297-304.	2.3	3
136	Getting to Grips with Individual Variation in Membrane Function. <i>Peritoneal Dialysis International</i> , 2005, 25, 35-37.	2.3	2
137	l-Carnitine: more than just an alternative to glucose as an osmotic agent for peritoneal dialysis?. <i>Kidney International</i> , 2011, 80, 565-566.	5.2	2
138	Technique Failure – Talking a Common Language. <i>Peritoneal Dialysis International</i> , 2016, 36, 583-584.	2.3	2
139	Normalizing the peritoneal dialysis dose – have we got it right?. <i>Kidney International</i> , 2016, 90, 1162-1163.	5.2	2
140	Reaching consensus on the important outcomes for peritoneal dialysis patients. <i>Kidney International</i> , 2019, 96, 545-546.	5.2	2
141	Renal staffs’ understanding of patients’ experiences of transition from peritoneal dialysis to in-centre haemodialysis and their views on service improvement: A multi-site qualitative study in England and Australia. <i>PLoS ONE</i> , 2021, 16, e0254931.	2.5	2
142	Intervening to eliminate the centre-effect variation in home dialysis use: protocol for Inter-CEPT – a sequential mixed-methods study designing an intervention bundle. <i>BMJ Open</i> , 2022, 12, e060922.	1.9	2
143	Monitoring residual kidney function in haemodialysis patients using timed urine collections: validation of the use of estimated blood results to calculate GFR. <i>Physiological Measurement</i> , 0, , .	2.1	2
144	Peritoneal Dialysis after a Failed Transplant. , 2006, 150, 271-277.		1

#	ARTICLE	IF	CITATIONS
145	Optimizing automated peritoneal dialysis: increasing nightly dialysate flow vs adding a manual daytime exchange. <i>Nature Clinical Practice Nephrology</i> , 2007, 3, 248-249.	2.0	1
146	Over-representation of diabetic patients with renal anaemia in the primary care setting. <i>Family Practice</i> , 2009, 26, 180-182.	1.9	1
147	Peritoneal Dialysis Research in the UK: The Cardiff Contribution. <i>Peritoneal Dialysis International</i> , 2011, 31, 39-42.	2.3	1
148	Getting More Out of Clinical Practice Guidelines. <i>Peritoneal Dialysis International</i> , 2011, 31, 631-635.	2.3	1
149	Does alanyl-glutamine supplementation offer potential to improve peritoneal dialysate biocompatibility?. <i>Kidney International</i> , 2018, 94, 1050-1052.	5.2	1
150	Providing care for patients with kidney failure over the next decade. <i>Kidney International</i> , 2020, 98, 1062-1063.	5.2	1
151	Raising the standard of trial registration, conduct, and reporting. <i>Peritoneal Dialysis International</i> , 2020, 40, 112-114.	2.3	1
152	Peritoneal Membrane Dysfunction. , 2017, , 451-460.e2.		1
153	Adequacy of Dialysis and Dietary Advice. , 2009, , 235-250.		1
154	Peritoneal Dialysis Solutions. , 2005, , 534-552.		1
155	Enriching the Evidence Base for Icodextrin. <i>American Journal of Kidney Diseases</i> , 2020, 75, 821-823.	1.9	1
156	EAPOS: what have we learned?. <i>Peritoneal Dialysis International</i> , 2007, 27, 131-5.	2.3	1
157	Examine the Individual, Not the Species.... <i>Nephron Clinical Practice</i> , 2003, 95, c1-c2.	2.3	0
158	The Authors Reply.. <i>Kidney International</i> , 2015, 87, 240.	5.2	0
159	SP435 VARIATION IN THE TREATMENT AND PREVENTION OF PERITONEAL DIALYSIS RELATED INFECTIONS: PRELIMINARY RESULTS FROM THE PERITONEAL DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (PDOPPS). <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i236-i237.	0.7	0
160	Writing for <i>Peritoneal Dialysis International</i> . <i>Peritoneal Dialysis International</i> , 2016, 36, 121-121.	2.3	0
161	Response to Koratala et al.. <i>International Journal of Cardiology</i> , 2017, 234, 109-110.	1.7	0
162	The Authors Reply. <i>Kidney International</i> , 2017, 92, 1290.	5.2	0

#	ARTICLE	IF	CITATIONS
163	Fluid Assessment in Peritoneal Dialysisâ€”There is Still a Place for Clinical Acumen. Peritoneal Dialysis International, 2018, 38, 81-82.	2.3	0
164	Local solutions save young lives. Nature Reviews Nephrology, 2019, 15, 127-128.	9.6	0
165	Understand the difference between clinical measured ultrafiltrationand real ultrafiltration in peritoneal dialysis. BMC Nephrology, 2021, 22, 382.	1.8	0